Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted daratumumab + lenalidomide + dexamethasone with autologous stem cell transplantation for newly diagnosed multiple myeloma
jRCTs071210074Active, not recruiting
- Sponsor
- Kyushu University Hospital
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of daratumumab, lenalidomide, dexamethasone, carfilzomib, melphalan and 2 more in multiple myeloma (MM) (3 arms), sponsored by Kyushu University Hospital. Primary endpoint: Complete response or better after consolidation therapy. Started Oct 2021; status: active, not recruiting.
02
Drugs
daratumumablenalidomidedexamethasonecarfilzomibmelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071210074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210074.